Why BGPT?
logo

Check Claims Before You Publish

See how your reported results read as versioned evidence records — linked to experiments and limitations.Know what the science actually supports before you trust the answer.

Press Enter ↵ to review claims



    Explore by Goal












     Quick Explanation


    Author scientific strength snapshot (critical)
    Based only on the metadata you provided (h-index, citations, paper titles/counts), I can’t verify methods/results/rigor from full texts or DOIs, so any “scientific strength” judgment is necessarily low-confidence.
    Key red-flag: the provided paper list appears to span multiple clinical subareas and one AI/self-supervised learning item; without full bibliographic records + full text, misattribution across similarly named authors is possible.



     Long Explanation


    John Y W Lee — Critical Scientific Author Review (metadata-limited)

    Date context: May 02, 2026 (as stated by you). Evidence base: only the author metrics + paper titles you provided in the prompt.

    1) Visual evidence from the provided citation metrics

    What this does / doesn’t tell you: These metrics describe impact proxies at a surface level. They do not verify experimental rigor, reproducibility, statistical correctness, or biological validity.

    2) Topic breadth signal from the titles you provided

    Interpretation (skeptical): A small publication set (8 papers, per your prompt) makes it easy for a researcher’s “topic distribution” to look broad or fragmented. That can reflect legitimate multi-disciplinary work (e.g., translational immunology + ML methods), or it can reflect co-authorship on heterogeneous projects.

    3) Scientific strength assessment — what I can and cannot verify

    Evidence you gave me (verifiable):
    • You provided citation metrics: h-index = 2, total citations = 4, paper count = 8.
    • You provided an explicit list of 8 paper titles (some clearly clinical/psoriasis/remote monitoring/reviews, one ML gene program-centric cell-state work).
    • You also provided OpenAlex matches, but the matches include multiple similarly named “John Y. W. Lee” variants, which increases the risk of mixing identities.
    What I cannot verify (therefore: low confidence):
    • No DOIs / venues / full texts were supplied for the 8 papers, so I cannot inspect study design, statistical methods, assumptions, bias controls, effect sizes, or data availability.
    • I cannot check whether systematic reviews were registered (e.g., protocol preregistration), whether meta-analyses used appropriate models/heterogeneity handling, or whether ML studies used rigorous evaluation (e.g., leakage prevention, external validation).
    • I cannot confirm reproducibility artifacts (code, data, supplementary methods).

    4) Epistemic critique: likely failure modes to check next

    Because your dataset is metadata-only, the dominant scientific risks are not about the biology per se, but about identity conflation and unverified rigor.
    • Author misattribution risk: OpenAlex shows multiple separate author entities for similar names; citation metrics can be misassigned if the wrong “John Y W Lee” is matched.
    • Publication bias & small-n effects: with h-index 2 and total citations 4 (per your prompt), the citation footprint could be dominated by one or two works, making impact proxies fragile.
    • Systematic review bias possibilities: without protocol/PRISMA/MOOSE details, it’s impossible to assess risk of selective study inclusion, selective outcome reporting, or inadequate heterogeneity handling.
    • Remote monitoring / AI image pipelines: without methods, I can’t evaluate whether performance was assessed with leakage-safe splitting and whether calibration/robustness were tested.
    • Generalization across cohorts: psoriasis populations are heterogeneous; without cohort description and external validation, generalization claims can be overstated.

    5) Scored estimates (critical; metadata-limited)

    Dimension Score (1–10) Why (skeptical, concise)
    Scientific quality3Cannot inspect methods/results; only titles + surface metrics provided.
    Scientific rigor3No full-text/statistics/preregistration/data availability details available.
    Communication5Titles suggest domain engagement, but writing clarity is unassessable without abstracts/manuscripts.
    Novelty4One ML-related title suggests ML novelty potential, but scope is unverifiable without the paper.
    Confidence: Low, because none of the paper-level evidence (methods, stats, data) was provided—only citations/metric proxies and titles.

    6) How to improve this author review (actionable next step)

    Provide these for each of the 8 papers
    • DOI + venue + year (or full bibliographic record)
    • Abstract + any methods/statistics highlights
    • For reviews/meta-analyses: PRISMA/MOOSE checklist details, number of included studies, effect sizes, heterogeneity metrics, risk-of-bias tool
    • For ML/AI: dataset size, labeling strategy, split strategy (leakage checks), external validation, calibration/robustness, and confusion-matrix style outputs

    Run a science agent to complete the audit

    If you can share DOIs or PDFs, the agent can pull full-text evidence and produce a real, citation-grounded rigor assessment.


    Feedback:    

    Updated: May 02, 2026

     BGPT Author Review


    Scientific Quality

    30%

    I’m forced to judge with only surface metrics (h-index=2, total citations=4, paper count=8) and titles. That is insufficient to assess biological validity, statistical correctness, bias controls, reproducibility, or effect-size credibility. Additionally, OpenAlex-style name collisions across “John Y.W. Lee” variants create substantial misattribution risk. Strength is plausible (one AI/self-supervised and several systematic-review/clinical implementation themes), but I cannot verify.


    Communication Quality

    50%

    Communication quality (clarity, structure, transparency, limitations) is not assessable without abstracts/full text. Titles suggest engagement with both clinical and AI topics, but title-only review is weak; hence mid score.


    Author Novelty

    40%

    Novelty cannot be confirmed without reading the ML paper(s) and the review methodology. The presence of a self-supervised gene program-centric cell-state title suggests potential novelty, but it could be incremental; title-only uncertainty keeps this modest.


    Scientific Rigor

    30%

    Rigor depends on methods details: preregistration, inclusion/exclusion, risk-of-bias, heterogeneity handling, leakage-safe ML evaluation, external validation, calibration, and data/code availability. None of that is provided, so rigor cannot be verified; score is low due to missing evidence and identity-collision risk.

     Analysis Wizard



    It would extract per-paper bibliographic identifiers, classify study designs, and compute a rigor checklist summary from methods sections, then output a sortable table of risks (bias, validation, reporting) for each DOI.



     Hypothesis Graveyard


    A single small cohort’s “significant” association between systemic inflammation markers and psoriasis severity is unlikely to be a stable causal biomarker claim without external replication and rigorous confounder control; cross-sectional designs often collapse multiple sources of variation.


    Claiming that AI image analysis “assesses severity” universally is unlikely to remain valid without calibration/validation across device/site shifts and without demonstrating invariance to acquisition protocol differences.

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending